Skip to main content
25 search results for:

Everolimus 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 31-05-2022 | Breast cancer | News | Article
    News in brief

    Everolimus ‘not recommended’ in adjuvant early breast cancer setting

    The addition of everolimus to standard adjuvant endocrine therapy does not improve the outcomes of women with hormone receptor-positive, HER2-negative early breast cancer at high risk for recurrence, show phase 3 trial results.

  2. 04-06-2022 | ASCO 2022 | Conference coverage | Article

    Adjuvant everolimus may benefit RCC patients at high risk for recurrence

    Adjuvant everolimus may improve recurrence-free survival after nephrectomy in people with treatment-naïve renal cell carcinoma, particularly those with a very high risk for recurrence, suggest final results from the EVEREST trial.

  3. 01-10-2021 | Breast cancer | News | Article

    First-line everolimus plus letrozole prolongs PFS of premenopausal breast cancer patients

    Premenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer derive a significant progression-free survival benefit from the addition of everolimus to first-line letrozole, shows the MIRACLE trial.

  4. 23-04-2021 | Renal cell carcinoma | News | Article

    Lenvatinib–everolimus has ‘encouraging activity’ in untreated non-clear cell RCC

    Previously untreated patients with advanced non-clear cell renal cell carcinoma could benefit from treatment with lenvatinib plus everolimus, suggests a phase 2 study.

  5. 20-02-2020 | ASCO GU 2020 | News | Article

    CheckMate 025: Superiority of nivolumab over everolimus confirmed in advanced RCC

    The final 5-year analysis of the CheckMate 025 trial comprising patients with advanced renal cell carcinoma confirms the enhanced survival benefits of nivolumab versus everolimus. This independent news story was supported by an educational grant from Pfizer and Merck KGaA

  6. 31-03-2017 | Everolimus | News | Article

    Commercial mouthwash substantially reduces everolimus-related stomatitis

    An inexpensive, commercially available dexamethasone mouthwash substantially reduces the incidence and severity of stomatitis in patients receiving everolimus and exemestane for breast cancer, US study data show.

  7. 16-12-2021 | Immunotherapy | News | Article

    HLA-A*03 shows potential as a biomarker for ICI response

    These analyses showed that HLA-A*03 carriers who received nivolumab had a significant 1.31-fold higher risk for disease progression or death than noncarriers, but there was no such association among people who received everolimus.

  8. 18-10-2021 | Renal cell carcinoma | News | Article

    PARP1 may predict ICI response in patients with advanced RCC

    For the current study, they used genomic and clinical data from 311 participants of clinical trials of PD-1 blockade in the advanced ccRCC setting, 181 of whom received nivolumab, while the remaining 130 received everolimus.

  9. 19-08-2021 | COVID-19 | News | Article

    Certain anticancer therapies linked to reduced SARS-CoV-2 infection rates

    The compounds in question were the mTOR/PI3K inhibitors everolimus, temsirolimus, and alpelisib, the antimetabolites gemcitabine and decitabine, the mitotic inhibitor cabazitaxel, and the kinase inhibitors crizotinib and dasatinib.

  10. 09-06-2021 | ASCO 2021 | Conference coverage | Article

    HRQoL data favor lenvatinib–pembrolizumab over sunitinib in advanced RCC

    Motzer reported that patients who received lenvatinib plus everolimus generally had similar HRQoL scores to those who received sunitinib.

  11. 16-02-2021 | ASCO GU 2021 | Conference coverage | Article

    Lenvatinib plus pembrolizumab achieve CLEAR survival advantage for clear cell RCC

    Median duration of response was 25.8 months with lenvatinib plus pembrolizumab, 16.6 months with lenvatinib plus everolimus, and 14.6 months with sunitinib.

  12. 28-07-2020 | Renal cell carcinoma | At a glance | Article

    At a glance: The CheckMate RCC trials

    The superiority of nivolumab over everolimus was confirmed in the final efficacy analysis, conducted at a minimum follow-up of 5 years and published in Cancer  in 2020. 

  13. 22-10-2019 | Renal cell carcinoma | News | Article

    Benefit of nivolumab–tivozanib, nivolumab beyond progression shown in metastatic RCC

    The cohort included patients with an IMDC favorable (19.3%), intermediate (48.6%), poor (27.5%), or unknown (4.6%) risk prognosis, and all but two patients had received at least one prior line of treatment before nivolumab, such as sunitinib, pazopanib, or everolimus.

  14. 12-06-2020 | ASCO 2020 | Conference coverage | Article

    RCC studies identify biomarkers of PD-1 inhibitor outcomes

    No such associations between the biomarker and outcomes were observed in the everolimus treatment arm, said Miriam Ficial of Brigham and Women's Hospital in Boston, Massachusetts, USA.

  15. 18-02-2020 | ASCO GU 2020 | News | Article

    Further investigation of combined immunotherapy, SBRT may be warranted for mRCC

    The ORR of 25% with nivolumab was reported previously in the CheckMate 025 trial of the PD-1 inhibitor versus everolimus in patients with advanced RCC.

  16. 06-02-2018 | Renal cell carcinoma | News | Article
    News in brief

    Cabozantinib slows time to deterioration in METEOR patients

    METEOR findings show that cabozantinib may prolong time to deterioration compared with everolimus, but suggest that the multikinase inhibitor has no significant impact on quality of life in patients with advanced renal cell carcinoma.

  17. 19-01-2018 | Renal cell carcinoma | News | Article
    News in brief

    METEOR supports cabozantinib for patients with advanced RCC and bone metastases

    Treatment with the multikinase inhibitor cabozantinib is associated with better outcomes than everolimus therapy in patients with previously treated advanced renal cell carcinoma and bone involvement, suggests a prespecified subgroup analysis of the phase III METEOR trial.

  18. 15-11-2018 | Renal cell carcinoma | News | Article

    Genomic annotation improves MSKCC risk model for renal carcinoma

    Similar results were observed for the patients in the validation cohort who were receiving treatment with everolimus and sunitinib.

  19. 13-03-2017 | Neuroendocrine tumors | Article

    Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract

    This review summarizes recent advances in the therapy of advanced gastroenteropancreatic-neuroendocrine tumors, delineating possible approaches for the management of this heterogeneous group of malignancies. Cives M & Strosberg J.  Curr Treat Options in Oncol 2017; 18: 14. doi:10.1007/s11864-017-0461-5

  20. 04-08-2016 | Renal cell carcinoma | Article

    Medical treatment of renal cancer: new horizons

    Patients were randomised to lenvatinib, everolimus or a combination of both drugs.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.